Investor Relations

Overview

Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: Xenleta™ (lefamulin), recently approved by the FDA for both Oral and IV use, and CONTEPO (fosfomycin) for injection. We resubmitted an NDA for CONTEPO, a potential first-in-class epoxide antibiotic in the United States for complicated urinary tract infections (cUTIs), including acute pyelonephritis (AP). The FDA has assigned a PDUFA date of June 19,2020 for CONTEPO. Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA.

Events & Presentations

Upcoming

Thursday June 4, 2020 1:00 PM EDT
Jefferies Virtual Healthcare Conference

Prior

Wednesday May 13, 2020 11:00 AM EDT
BofA Securities 2020 Virtual Health Care Conference

Tuesday April 14, 2020 11:20 AM EDT
19th Annual Needham Healthcare Conference.

SEC Filings

Filing date Description Form Filing Group View

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

424B5
Registration Statements
View HTML

Report of unscheduled material events or corporate event

8-K
Current Reports
View HTML

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

424B5
Registration Statements
View HTML

Investor Contacts

E-mail: IR@nabriva.com